Pipeline, Formulations, and Opportunities
We are currently in a Phase 2b clinical trial of AMTX-100 CF3 as a potential best-in-class topical treatment for mild to moderate atopic dermatitis (eczema), an inflammatory skin disease affecting more than 31 million people in the U.S. alone. Atopic dermatitis, among other skin conditions, can be highly visible and cause mild to severe physical discomfort and disability, impacting nearly all aspects of a patient’s life including social interactions and mental health. Amytrx’s FDA-approved pre-clinical studies in our atopic dermatitis IND cover several other inflammatory skin conditions, including psoriasis, rosacea, acne, lupus and viral infections.
Amytrx's pipeline is supported by numerous animal studies of human disease and pre-clinical and clinical safety. We are focused on developing our lead compound AMTX-100 in a variety of formulations to enhance specificity and safety of therapeutic delivery—whether by systemic or high-concentration localized delivery—across a range of chronic inflammatory and autoimmune diseases.
AMTX-100 Topical Formulations & Pipeline
Other Formulation Opportunities
We appreciate the role of volunteers who enroll in clinical trials—with their critical participation, we are able to evaluate and advance potential new therapies that can aid in restoring the health of millions of patients.
Amytrx will begin enrollment in the Phase 2b portion of an adaptive Phase 1/2b clinical trial of AMTX-100 CF3 in the skin disease, atopic dermatitis (eczema) later in 2022. For more information on this study, please visit clinicaltrials.gov.
Medical professionals can visit our contact page to email a request for more information about clinical trial participation.